Pacific Edge (PEB)

• What is the current status of the Medicare coverage appeal, and does management have any legal or regulatory basis for the six-to-nine month timeline estimate?
• How does the board plan to fund operations if the appeal extends beyond the current cash position — is a capital raise already under active consideration?
• What specific cost actions, if any, are planned to reduce the NZ$19M half-year cash burn while the appeal is pending?
• Will test volumes delivered but not yet recognised as revenue under Medicare be retrospectively billable upon a successful appeal, and under what conditions might those volumes be partially or fully unrecoverable?
• Is the 5.8% quarter-on-quarter improvement in tests per sales FTE representative of a sustainable trend, or is it partly explained by the smaller sales force denominator?

This briefing cannot assess the probability or timing of a successful Medicare coverage reinstatement, which is the single variable that most determines Pacific Edge's near-term financial viability.